Kane Biotech Inc.

TSXV:KNE Stock Report

Market Cap: CA$13.8m

Kane Biotech Management

Management criteria checks 2/4

Kane Biotech's CEO is Marc Edwards, appointed in Sep 2018, has a tenure of 6.25 years. total yearly compensation is CA$406.83K, comprised of 61.5% salary and 38.5% bonuses, including company stock and options. directly owns 4.64% of the company’s shares, worth CA$638.31K. The average tenure of the management team and the board of directors is 2.7 years and 6.3 years respectively.

Key information

Marc Edwards

Chief executive officer

CA$406.8k

Total compensation

CEO salary percentage61.5%
CEO tenure6.3yrs
CEO ownership4.6%
Management average tenure2.7yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

Nov 05
Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

Is Kane Biotech (CVE:KNE) A Risky Investment?

Jul 14
Is Kane Biotech (CVE:KNE) A Risky Investment?

Is Kane Biotech (CVE:KNE) A Risky Investment?

Mar 27
Is Kane Biotech (CVE:KNE) A Risky Investment?

CEO Compensation Analysis

How has Marc Edwards's remuneration changed compared to Kane Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$5m

Jun 30 2024n/an/a

-CA$5m

Mar 31 2024n/an/a

-CA$5m

Dec 31 2023CA$407kCA$250k

-CA$5m

Sep 30 2023n/an/a

-CA$4m

Jun 30 2023n/an/a

-CA$4m

Mar 31 2023n/an/a

-CA$4m

Dec 31 2022CA$303kCA$242k

-CA$4m

Sep 30 2022n/an/a

-CA$4m

Jun 30 2022n/an/a

-CA$5m

Mar 31 2022n/an/a

-CA$5m

Dec 31 2021CA$329kCA$225k

-CA$5m

Sep 30 2021n/an/a

-CA$4m

Jun 30 2021n/an/a

-CA$4m

Mar 31 2021n/an/a

-CA$3m

Dec 31 2020CA$353kCA$225k

-CA$4m

Sep 30 2020n/an/a

-CA$4m

Jun 30 2020n/an/a

-CA$4m

Mar 31 2020n/an/a

-CA$2m

Dec 31 2019CA$311kCA$225k

-CA$960k

Sep 30 2019n/an/a

-CA$510k

Jun 30 2019n/an/a

-CA$685k

Mar 31 2019n/an/a

-CA$3m

Dec 31 2018CA$85kCA$67k

-CA$3m

Sep 30 2018n/an/a

-CA$4m

Jun 30 2018n/an/a

-CA$4m

Mar 31 2018n/an/a

-CA$4m

Dec 31 2017CA$18kn/a

-CA$3m

Compensation vs Market: Marc's total compensation ($USD282.19K) is above average for companies of similar size in the Canadian market ($USD163.59K).

Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.

CEO

Marc Edwards

6.3yrs

Tenure

CA$406,832

Compensation

Mr. Marc Edwards is the Founder and President of VetRx, a Montreal-based technology company specializing in daollection, cleansing, marketing and pharmaceutical compliance for the veterinary industry. Mr....

Leadership Team

NamePositionTenureCompensationOwnership
Marc Edwards
President6.3yrsCA$406.83k4.64%
CA$ 638.3k
Ray Dupuis
Chief Financial Officer7.3yrsCA$231.39k0.72%
CA$ 98.5k
Robert Huizinga
Executive Chairman & Member of Scientific Advisory Board6.3yrsno data0.24%
CA$ 33.2k
Gregory Schultz
Chief Scientific Officer & Member of Scientific Advisory Board2.7yrsno datano data
Lorne Gorber
Investor Relationsno datano datano data
Wendy Nachtigall
Director of Marketingno datano datano data
Lori Christofalos
Chief Quality Officerless than a yearno datano data
Nicole Sendey
Investor Relations Adviserno datano datano data

2.7yrs

Average Tenure

Experienced Management: KNE's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marc Edwards
President8.8yrsCA$406.83k4.64%
CA$ 638.3k
Robert Huizinga
Executive Chairman & Member of Scientific Advisory Board6.3yrsno data0.24%
CA$ 33.2k
Gregory Schultz
Chief Scientific Officer & Member of Scientific Advisory Board2.9yrsno datano data
Georges Morin
Independent Director4.6yrsCA$41.53k0.11%
CA$ 15.0k
Philip Renaud
Vice Chairman14.3yrsCA$44.73k18.46%
CA$ 2.5m
Rashieda Gluck
Member of Scientific Advisory Board6.3yrsCA$13.30kno data
Gordon Guay
Chairman of Scientific Advisory Board6.3yrsno datano data
John Coleman
Independent Director1.1yrsCA$2.25kno data

6.3yrs

Average Tenure

Experienced Board: KNE's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 07:19
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kane Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution